Loading organizations...
IntegenX is a technology company.
IntegenX develops rapid DNA technology for human identification, providing automated, on-site DNA analysis capabilities. The company's core product, exemplified by the RapidHIT 200 system, streamlines forensic human identification by significantly reducing the time required to analyze DNA samples. This innovative approach offers substantial improvements over traditional laboratory methods.
IntegenX was founded in 2006 by Stevan Jovanovich and Dennis Harris. Their foundational insight centered on the critical need for accelerated human identification processes, particularly within law enforcement and forensic science. The founders aimed to overcome the inherent delays of conventional DNA analysis, enabling faster investigative responses and critical decision-making.
The company's products serve law enforcement agencies and forensic laboratories seeking immediate human identification solutions. IntegenX’s vision is to advance public safety and justice by making rapid DNA analysis accessible and efficient. They empower authorities with swift, accurate genetic information, thereby enhancing investigative capabilities and supporting humanitarian efforts.
IntegenX has raised $84.0M across 4 funding rounds.
IntegenX has raised $84.0M in total across 4 funding rounds.
IntegenX has raised $84.0M in total across 4 funding rounds.
IntegenX's investors include Horizon Technology Finance, Square 1 Bank, Domain Associates, Cross Creek Advisors, Greenspring Associates, In-Q-Tel, Ben Schapiro, RONAholdings, Samsung Ventures, QuestMark Partners, Rona Syndicates, Bill Byun.
IntegenX is a biotechnology company that designs, manufactures, and markets automated systems for microsample preparation and analysis in life sciences, specializing in Rapid DNA technology for human identification.[1][2][5] Its flagship products include the RapidHIT System, a fully automated, self-contained platform that generates standardized DNA profiles from buccal swabs or other samples in about 90 minutes using gold-standard extraction, PCR, and capillary electrophoresis, serving forensics, law enforcement, and biodefense needs with minimal hands-on time (3 minutes for five profiles).[2][3] Additional offerings encompass the Apollo series for DNA sequencing library preparation (e.g., Apollo 324 NGS for nucleic acid isolation) and GenTegra products for ambient-temperature DNA/RNA storage.[1][2][3] The company raised $89.16M before being acquired by Thermo Fisher Scientific, establishing it as a market leader in rapid human DNA identification.[4][6]
IntegenX was co-founded in 2003 by Dr. Stevan Jovanovich (President and CEO) as Microchip Biotechnologies in Pleasanton, California, to optimize sample preparation for life sciences, particularly DNA sequencing, biodefense, and forensics.[1][4] Jovanovich, principal investigator on over $10M in grants, led commercialization efforts with a team leveraging microfluidics expertise; other key figures include Mostafa Ronaghi (Ph.D. from Sweden, 20+ patents, Stanford experience in molecular diagnostics) and serial entrepreneur involvement in building eight tech firms.[1] Early traction came from innovations like patented MOVe valve technology and PrepX kits, evolving from sequencing tools to forensic breakthroughs like RapidHIT, launched in Europe in 2012 amid law enforcement collaboration.[3]
IntegenX rides the Rapid DNA trend, accelerating forensics from days to hours, enabling field-deployable ID for law enforcement to identify offenders, exonerate innocents, and enhance biodefense—critical amid rising global crime and judicial backlogs.[3][5] Timing aligns with next-gen sequencing advances and demand for portable biotech, fueled by market forces like increased research funding and automated storage needs to combat sample degradation.[1][4] Its tech influences ecosystems by standardizing outputs for databases, partnering with agencies (e.g., FBI, EU forensics), and post-acquisition by Thermo Fisher, integrates into larger life sciences tools, boosting scalability in human ID and molecular diagnostics.[3][6]
Post-2018 acquisition by Thermo Fisher, IntegenX's RapidHIT platforms and consumables will likely expand globally via Thermo’s distribution, enhancing software tools and reagent compatibility for broader forensics adoption.[6] Trends like AI-driven analysis, portable biodefense, and rising gene therapy will shape growth, potentially evolving influence toward integrated lab-on-chip ecosystems for real-time ID in security and healthcare. This cements IntegenX's legacy from niche innovator to cornerstone of rapid life sciences automation.[4][6]
IntegenX has raised $84.0M across 4 funding rounds. Most recently, it raised $10.0M Debt in September 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 24, 2014 | $10.0M Debt | Horizon Technology Finance, Square 1 Bank | |
| Dec 1, 2011 | $40.0M Series C | Domain Associates, Cross Creek Advisors, Greenspring Associates, In-Q-Tel, Ben Schapiro, RONAholdings, Samsung Ventures | |
| Feb 1, 2011 | $16.0M Series B | Domain Associates | Cross Creek Advisors, Greenspring Associates, In-Q-Tel, QuestMark Partners, RONAholdings |
| Nov 1, 2009 | $18.0M Series B | Domain Associates | In-Q-Tel, Rona Syndicates, Bill Byun, Western Technology Investment |